EKF Diagnostics Holdings plc provided trading update for the six months ended June 30, 2012. Adjusted EBITDA for the period is expected to be well ahead of market expectations, due to the company's decision to increase its sales focus on its higher margin products, in particular Beta-Hydroxybutyrate (BHB) liquid reagents and the Board is confident that the company is on track to meet or exceed current earnings expectations for the full year. Unaudited revenues for the period are expected to be approximately £12.65 million.